<?xml version="1.0" encoding="UTF-8"?>
<p>Common clinical manifestations of patients with COVID-19 include fever and cough, and less commonly fatigue, dyspnea, headache, sore throat, anosmia, nausea, vomiting, or diarrhea.
 <sup>
  <xref rid="bibr6-1358863X20932640" ref-type="bibr">6</xref>
 </sup> In the largest case series to date of over 44,000 patients with COVID-19, &gt; 75% of cases were mild, 14% were severe, and 5% were critical, with an overall case fatality rate of 2–2.5%. All deaths occurred in patients with critical disease (in which the case fatality rate was almost 50%).
 <sup>
  <xref rid="bibr19-1358863X20932640" ref-type="bibr">19</xref>
 </sup> While the majority of critically ill patients with COVID-19 have isolated respiratory failure, often acute respiratory distress syndrome (ARDS), multiple organ dysfunction occurs in 20–30% of patients with critical illness and more often in fatal cases.
 <sup>
  <xref rid="bibr16-1358863X20932640" ref-type="bibr">16</xref>
 </sup> Hematologic findings, such as mild to moderate thrombocytopenia and lymphopenia, are associated with COVID-19;
 <sup>
  <xref rid="bibr20-1358863X20932640" ref-type="bibr">20</xref>,
  <xref rid="bibr21-1358863X20932640" ref-type="bibr">21</xref>
 </sup> however, the most significant and concerning vascular aspect of this disease is coagulopathy. We have attempted to summarize the data on the pathogenesis, epidemiology and outcomes related to COVID-19-coagulopathy and thrombotic disease using PubMed as well as the pre-print server 
 <ext-link ext-link-type="uri" xlink:href="https://medrxiv.org" xmlns:xlink="http://www.w3.org/1999/xlink">https://medrxiv.org</ext-link> (date of last search April 23, 2020).
</p>
